Newsroom | 40673 results
Sorted by: Latest
-
Align Technology to Speak at Upcoming Financial Conferences
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at upcoming financial conferences. As noted below, the presentations will be webcast live via the Investor Relations section of Align Te...
-
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,...
-
Reflow Medical Reports Six-Month Results from DEEPER CORONARY Study of Spur® Elute Stent
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Reflow Medical announces six-month DEEPER CORONARY study results for the Spur® Elute Sirolimus-Eluting Retrievable Stent System at EuroPCR 2026....
-
Vyriad Launches G-Link: A Modular Platform Advancing T-Cell Targeted Lentiviral Vector Delivery for In Vivo and Ex Vivo Applications
ROCHESTER, Minn.--(BUSINESS WIRE)--G-Link is a first-in-class modular adaptor protein technology designed to enable and enhance T-cell-targeting delivery across CAR T workflows....
-
InSphero AG Acquires PhenoVista Biosciences, Inc. to Expand Advanced 3D, Cell-based Assay Capabilities
SCHLIEREN, Switzerland & SAN DIEGO--(BUSINESS WIRE)--InSphero AG, a global leader in advanced 3D in vitro models and services for drug safety and efficacy testing, today announced the acquisition of PhenoVista Biosciences, Inc., a premier provider of high-content imaging and phenotypic assay technologies based in San Diego, California. The acquisition marks an important new chapter for PhenoVista Biosciences, enabling the company to significantly expand its scientific and commercial impact by c...
-
InterSystems IntelliCare wird das erste KI-native KIS mit Zertifizierung nach der EU-Medizinprodukteverordnung
BOSTON--(BUSINESS WIRE)--InterSystems, ein Anbieter kreativer Datentechnologien, dessen Lösungen weltweit mehr als eine Milliarde Gesundheitsakten unterstützen, gab heute bekannt, dass seine Krankenhausinformationssystem (KIS)-Lösungen als Medizinprodukte der Klasse IIa gemäß der Medizinprodukteverordnung (MDR) nach Verordnung (EU) 2017/745 zertifiziert wurden. Mit dieser Zulassung ist das erste vollständig integrierte KI-native KIS in der Europäischen Union nach MDR Klasse IIa zertifiziert. Di...
-
Jupiter Endovascular Announces Positive Results From SPIRARE II Pivotal Trial at EuroPCR 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--Jupiter Endovascular announced positive results from its SPIRARE II pivotal trial at EuroPCR showing the trial met both of its primary endpoints....
-
InterSystems IntelliCare jako pierwsza elektroniczna dokumentacja medyczna z założenia oparta na AI otrzymuje certyfikat zgodnie z unijnym rozporządzeniem w sprawie wyrobów medycznych
BOSTON--(BUSINESS WIRE)--InterSystems, kreatywny dostawca technologii w zakresie danych, który obsługuje ponad 1 mld rejestrów zdrowotnych na całym świecie, poinformował dzisiaj, że jego rozwiązania z zakresu elektronicznej dokumentacji medycznej (ang. EHR) uzyskały certyfikat jako wyroby medyczne klasy IIa zgodnie z rozporządzeniem (UE) 2017/745 w sprawie wyrobów medycznych (ang. MDR). Są to zarazem pierwsze w pełni ujednolicone rozwiązania EHR z założenia oparte na AI, które uzyskały certyfik...
-
Predicta Biosciences Appoints Dr. Craig L. Tendler as Independent Director to its Board
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Predicta Biosciences, a company building ultra-sensitive molecular and immune diagnostic platforms, today announced the appointment of Craig L. Tendler, M.D., as an independent director to its Board of Directors. Dr. Tendler brings decades of experience designing and executing oncology and hematology development programs including the integration of biomarkers and diagnostics, from early development and proof of concept through registration. Over the course of...
-
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total...